Bill > HB2145

This bill aims to protect patient access to discounted medications and healthcare services by preventing drug manufacturers from limiting participation in the federal 340B drug pricing program, a program established in 1992 that requires manufacturers to offer discounts on outpatient medications to eligible healthcare providers serving low-income and uninsured populations, such as federally qualified health centers and safety net hospitals. The bill defines key terms like "340B drug," "340B program," "covered entity" (which includes affiliated offsite facilities), "manufacturer," and "pharmacy," and prohibits manufacturers or their representatives from denying or restricting the acquisition or delivery of 340B drugs to covered entities or their contracted pharmacies, or from requiring data submission as a condition for these drugs unless federal law mandates it. Violations can result in civil penalties of up to $5,000 per day per package of drugs, and the Attorney General can bring actions under the consumer protection act. Additionally, hospital covered entities must annually report detailed information about their 340B program participation, savings, and how these savings benefit their communities to the Department of Health, which will make this information public and can impose fines for non-compliance. The bill also includes a severability clause and a nullification clause if specific funding is not provided by June 30, 2026.

Budget and Finance, Health and Social Services

https://app.leg.wa.gov/billsummary?BillNumber=2145&Year=2025&Initiative=false